These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

179 related items for PubMed ID: 22231445

  • 1. STAP-2 interacts with and modulates BCR-ABL-mediated tumorigenesis.
    Sekine Y, Ikeda O, Mizushima A, Ueno Y, Muromoto R, Yoshimura A, Kanakura Y, Oritani K, Matsuda T.
    Oncogene; 2012 Oct 04; 31(40):4384-96. PubMed ID: 22231445
    [Abstract] [Full Text] [Related]

  • 2. CCR7 is involved in BCR-ABL/STAP-2-mediated cell growth in hematopoietic Ba/F3 cells.
    Kubo K, Iwakami M, Muromoto R, Inagaki T, Kitai Y, Kon S, Sekine Y, Oritani K, Matsuda T.
    Biochem Biophys Res Commun; 2015 Aug 07; 463(4):825-31. PubMed ID: 26102025
    [Abstract] [Full Text] [Related]

  • 3. Positive interactions between STAP-1 and BCR-ABL influence chronic myeloid leukemia cell proliferation and survival.
    Ishiura M, Kitai Y, Kashiwakura JI, Muromoto R, Toda J, Ichii M, Oritani K, Matsuda T.
    Biochem Biophys Res Commun; 2021 Jun 04; 556():185-191. PubMed ID: 33845308
    [Abstract] [Full Text] [Related]

  • 4. Inhibition of Abl tyrosine kinase enhances nerve growth factor-mediated signaling in Bcr-Abl transformed cells via the alteration of signaling complex and the receptor turnover.
    Koch A, Scherr M, Breyer B, Mancini A, Kardinal C, Battmer K, Eder M, Tamura T.
    Oncogene; 2008 Aug 07; 27(34):4678-89. PubMed ID: 18427551
    [Abstract] [Full Text] [Related]

  • 5. Signal-transducing adapter protein-1 is required for maintenance of leukemic stem cells in CML.
    Toda J, Ichii M, Oritani K, Shibayama H, Tanimura A, Saito H, Yokota T, Motooka D, Okuzaki D, Kitai Y, Muromoto R, Kashiwakura JI, Matsuda T, Hosen N, Kanakura Y.
    Oncogene; 2020 Aug 07; 39(34):5601-5615. PubMed ID: 32661325
    [Abstract] [Full Text] [Related]

  • 6. Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia.
    Barnes DJ, Palaiologou D, Panousopoulou E, Schultheis B, Yong AS, Wong A, Pattacini L, Goldman JM, Melo JV.
    Cancer Res; 2005 Oct 01; 65(19):8912-9. PubMed ID: 16204063
    [Abstract] [Full Text] [Related]

  • 7. Phosphorylation levels of BCR-ABL, CrkL, AKT and STAT5 in imatinib-resistant chronic myeloid leukemia cells implicate alternative pathway usage as a survival strategy.
    Jilani I, Kantarjian H, Gorre M, Cortes J, Ottmann O, Bhalla K, Giles FJ, Albitar M.
    Leuk Res; 2008 Apr 01; 32(4):643-9. PubMed ID: 17900686
    [Abstract] [Full Text] [Related]

  • 8. Bcr-Abl kinase modulates the translation regulators ribosomal protein S6 and 4E-BP1 in chronic myelogenous leukemia cells via the mammalian target of rapamycin.
    Ly C, Arechiga AF, Melo JV, Walsh CM, Ong ST.
    Cancer Res; 2003 Sep 15; 63(18):5716-22. PubMed ID: 14522890
    [Abstract] [Full Text] [Related]

  • 9. IRF5 is a target of BCR-ABL kinase activity and reduces CML cell proliferation.
    Massimino M, Consoli ML, Mesuraca M, Stagno F, Tirrò E, Stella S, Pennisi MS, Romano C, Buffa P, Bond HM, Morrone G, Sciacca L, Di Raimondo F, Manzella L, Vigneri P.
    Carcinogenesis; 2014 May 15; 35(5):1132-43. PubMed ID: 24445143
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Selective pyrrolo-pyrimidine inhibitors reveal a necessary role for Src family kinases in Bcr-Abl signal transduction and oncogenesis.
    Wilson MB, Schreiner SJ, Choi HJ, Kamens J, Smithgall TE.
    Oncogene; 2002 Nov 21; 21(53):8075-88. PubMed ID: 12444544
    [Abstract] [Full Text] [Related]

  • 12. STAP-2 is phosphorylated at tyrosine-250 by Brk and modulates Brk-mediated STAT3 activation.
    Ikeda O, Miyasaka Y, Sekine Y, Mizushima A, Muromoto R, Nanbo A, Yoshimura A, Matsuda T.
    Biochem Biophys Res Commun; 2009 Jun 19; 384(1):71-5. PubMed ID: 19393627
    [Abstract] [Full Text] [Related]

  • 13. Differences in BCL-X(L) expression and STAT5 phosphorylation in chronic myeloid leukaemia patients.
    Gutiérrez-Castellanos S, Cruz M, Rabelo L, Godínez R, Reyes-Maldonado E, Riebeling-Navarro C.
    Eur J Haematol; 2004 Apr 19; 72(4):231-8. PubMed ID: 15089759
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Characterization of p87C3G, a novel, truncated C3G isoform that is overexpressed in chronic myeloid leukemia and interacts with Bcr-Abl.
    Gutiérrez-Berzal J, Castellano E, Martín-Encabo S, Gutiérrez-Cianca N, Hernández JM, Santos E, Guerrero C.
    Exp Cell Res; 2006 Apr 01; 312(6):938-48. PubMed ID: 16443220
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Growth of chronic myeloid leukemia cells is inhibited by infection with Ad-SH2-HA adenovirus that disrupts Grb2-Bcr-Abl complexes.
    Peng Z, Luo HW, Yuan Y, Shi J, Huang SF, Li CL, Cao WX, Huang ZG, Feng WL.
    Oncol Rep; 2011 May 01; 25(5):1381-8. PubMed ID: 21369701
    [Abstract] [Full Text] [Related]

  • 18. Tyrosine phosphorylation and activation of focal adhesion kinase (p125FAK) by BCR-ABL oncoprotein.
    Gotoh A, Miyazawa K, Ohyashiki K, Tauchi T, Boswell HS, Broxmeyer HE, Toyama K.
    Exp Hematol; 1995 Oct 01; 23(11):1153-9. PubMed ID: 7556524
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.